Manufacturing Samsung Biologics: geographic diversification is a sound business decision Pharmaceutical TechnologySamsung Biologics has been on a steep upward growth trajectory since receiving its first licence to produce biologic drug substances in 2015.Read full story pharminent July 22, 2026 (Last updated: July 23, 2026) Pharmaceutical Technology Samsung Biologics has been on a steep upward growth trajectory since receiving its first licence to produce biologic drug substances in 2015. Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Repligen builds in cell therapy with $1.5bn BioLife takeoverNext: Trump Threatens 100%–200% Tariffs on Imported Generic Drugs Related Stories Manufacturing Trump Threatens 100%–200% Tariffs on Imported Generic Drugs pharminent July 22, 2026 Manufacturing J&J Streamlines Pharma Supply Chain Amid $55B US Manufacturing Push pharminent July 15, 2026 Manufacturing Cellares and Sonoma partner to automate cell therapy manufacturing pharminent July 14, 2026
